Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Stefania Merighi, Enrica Battistello, Luca Giacomelli, Katia Varani, Fabrizio Vincenzi, Pier Andrea Borea & Stefania Gessi. (2019) Targeting A3 and A2A adenosine receptors in the fight against cancer. Expert Opinion on Therapeutic Targets 23:8, pages 669-678.
Read now
Read now
F. Javier Álvarez. (2016) Parkinson’s disease, antiparkinson medicines, and driving. Expert Review of Neurotherapeutics 16:9, pages 1023-1032.
Read now
Read now
Kjell Fuxe, Diego Guidolin, Luigi F Agnati & Dasiel O Borroto-Escuela. (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opinion on Therapeutic Targets 19:3, pages 377-398.
Read now
Read now
Articles from other publishers (18)
Ankita Wal, Pranay Wal, Himangi Vig, Nem Kumar Jain, Shruti Rathore, Karthickeyan Krishnan & Ashish Srivastava. (2023) Treatment of Parkinson's Disease: Current Treatments and Recent
Therapeutic Developments. Current Drug Discovery Technologies 20:5.
Crossref
Crossref
Moritz Ernst, Ann-Kristin Folkerts, Romina Gollan, Emma Lieker, Julia Caro-Valenzuela, Anne Adams, Nora Cryns, Ina Monsef, Antje Dresen, Mandy Roheger, Carsten Eggers, Nicole Skoetz & Elke Kalbe. (2023) Physical exercise for people with Parkinson’s disease: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2023:5.
Crossref
Crossref
Fillipe M. de Araújo, Lorena Cuenca-Bermejo, Emiliano Fernández-Villalba, Silvia L. Costa, Victor Diogenes A. Silva & Maria Trinidad Herrero. (2021) Role of Microgliosis and NLRP3 Inflammasome in Parkinson’s Disease Pathogenesis and Therapy. Cellular and Molecular Neurobiology 42:5, pages 1283-1300.
Crossref
Crossref
Carissa A. Hansen, Douglas R. Miller, Stephanie Annarumma, Carley T. Rusch, Adolfo Ramirez-Zamora & Habibeh Khoshbouei. (2022) Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment. Journal of Neurology 269:6, pages 2892-2909.
Crossref
Crossref
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2993
3013
.
Iryna Karaban, Nina Karasevych & Tetyana Hasiuk. (2021) Prospects of successful treatment of Parkinson's disease
using apomorphine. Ageing & Longevity:4 2021, pages 1-26.
Crossref
Crossref
Laura Yenisa CabreraCatherine Young HanTasha OstendorfJoohi Jimenez-Shahed & Harini Sarva. (2021) Neurologists' Attitudes Toward Use and Timing of Deep Brain Stimulation. Neurology Clinical Practice 11:6, pages 506-516.
Crossref
Crossref
I.M. Karaban, N.V. Karasevych & T.V. Hasiuk. (2021) Prospects for successful treatment of Parkinson’s disease with the use of apomorphine. INTERNATIONAL NEUROLOGICAL JOURNAL 17:4, pages 54-73.
Crossref
Crossref
Laura Tabacof, Stephen Braren, Taylor Patterson, Adam Fry & David Putrino. (2021) Safety and Tolerability of a Wearable, Vibrotactile Stimulation Device for Parkinson’s Disease. Frontiers in Human Neuroscience 15.
Crossref
Crossref
Charles D. Ciccone. 2020. Guccione's Geriatric Physical Therapy. Guccione's Geriatric Physical Therapy
102
136
.
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
21
.
Renata Ramina Pessoa, Adriana Moro, Renato Puppi Munhoz, Hélio A.G. Teive & Andrew J. Lees. (2018) Apomorphine in the treatment of Parkinson's disease: a review. Arquivos de Neuro-Psiquiatria 76:12, pages 840-848.
Crossref
Crossref
Jorgen Kjaergaard, Stephen Hatfield, Graham Jones, Akio Ohta & Michail Sitkovsky. (2018) A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression. The Journal of Immunology 201:2, pages 782-791.
Crossref
Crossref
Hossein Sanjari Moghaddam, Ameneh Zare-Shahabadi, Farzaneh Rahmani & Nima Rezaei. (2017) Neurotransmission systems in Parkinson’s disease. Reviews in the Neurosciences 28:5, pages 509-536.
Crossref
Crossref
Luxi Wang, Nian Xiong, Jinsha Huang, Shiyi Guo, Ling Liu, Chao Han, Guoxin Zhang, Haiyang Jiang, Kai Ma, Yun Xia, Xiaoyun Xu, Jie Li, Jing Y. Liu & Tao Wang. (2017) Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Gemma Navarro, Dasiel O. Borroto-Escuela, Kjell Fuxe & Rafael Franco. (2016) Purinergic signaling in Parkinson's disease. Relevance for treatment. Neuropharmacology 104, pages 161-168.
Crossref
Crossref
Peter Jenner. (2015) Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future. Translational Neurodegeneration 4:1.
Crossref
Crossref
I. G. Silkis. (2014) The reasons for the preferable use of A2A receptor antagonists for improvement of locomotor activity and learning. Neurochemical Journal 8:4, pages 247-258.
Crossref
Crossref